These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36335780)

  • 1. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
    Véron M; Chevret S; Grob JJ; Beylot-Barry M; Saiag P; Fléchon A; You B; Maubec E; Jouary T; Toulemonde E; Jamme P; Gambotti L; Lamrani-Ghaouti A; Dupuy A; Lebbe C; Seguin NB; Houede N; Leccia MT; Le Du F; de Pontville M; Gaudy-Marquestre C; Guillot B; Simon C; Marabelle A; Mortier L
    Eur J Cancer; 2022 Dec; 177():103-111. PubMed ID: 36335780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
    Toulemonde E; Chevret S; Battistella M; Neidhardt EM; Nardin C; Le Du F; Meyer N; Véron M; Gambotti L; Lamrani-Ghaouti A; Jamme P; Chaffaut C; De Pontville M; Saada-Bouzid E; Beylot-Barry M; Simon C; Jouary T; Marabelle A; Mortier L
    Cancer Immunol Immunother; 2023 Aug; 72(8):2649-2657. PubMed ID: 37067554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
    Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
    Mesti T; Sever M; Ocvirk J
    Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
    Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
    Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
    Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current clinical approach to difficult-to-treat basal cell carcinomas.
    Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments on the horizon for locally advanced basal cell carcinoma.
    Idriss MH; Stull CM; Migden MR
    Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
    Zelin E; Mazzoletti V; Cavallo F; Nardello C; Corio A; Toffoli L; Tagliaferri L; Conforti C; Di Meo N; Zalaudek I
    Australas J Dermatol; 2024 Mar; 65(2):103-113. PubMed ID: 37927116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Targeted Treatments for Basal Cell Carcinoma.
    Svoboda SA; Johnson NM; Phillips MA
    Cutis; 2022 Jun; 109(6):E25-E31. PubMed ID: 35960978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of caregivers for patients with advanced basal cell carcinoma treated with hedgehog-pathway inhibitors: an observational prospective study.
    Trane L; Salvati L; Silvestri F; Venturi F; Zuccaro B; Perillo G; De Giorgi V
    Eur J Dermatol; 2024 Feb; 34(1):68-72. PubMed ID: 38557461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.